Drug intelligence / Profile preview

gemcitabine + ramucirumab

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

Gemcitabine + ramucirumab is a combination therapy consisting of the nucleoside analogue antimetabolite gemcitabine and the monoclonal antibody ramucirumab. Gemcitabine inhibits DNA synthesis, while ramucirumab targets vascular endothelial growth factor receptor 2 (VEGFR-2), blocking angiogenesis. This combination has been investigated in clinical trials for second-line treatment of malignant pleural mesothelioma after progression on first-line platinum/pemetrexed chemotherapy, showing improved overall survival and a favorable safety profile[1][2][5].

Other names: gemcitabine plus ramucirumabramucirumab plus gemcitabine

Targets

POLA1 (DNA polymerase alpha)VEGFR2 (Vascular endothelial growth factor receptor 2)

Beyond the preview

Go deeper on gemcitabine + ramucirumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gemcitabine + ramucirumab.

Explore the full profile